Skip to main
JANX

Janux Therapeutics (JANX) Stock Forecast & Price Target

Janux Therapeutics (JANX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 17%
Sell 8%
Strong Sell 0%

Bulls say

Janux Therapeutics is a biopharmaceutical company with a strong focus on developing tumor-activated immunotherapies for cancer. Its proprietary TRACTr, TRACIr, and ARM platforms utilize tumor-activated masking technology, which improves specificity and safety. With a robust pipeline of potential treatments, impressive financial backing, and ongoing clinical trials showing promising results, the company is well-positioned for success and has the potential to transform T-cell engager approaches in both oncology and autoimmune diseases.

Bears say

Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing tumor-activated immunotherapies for cancer. While its proprietary technology allows for the development of distinct bispecific platforms, the company's lead asset, JANX007, may face challenges in the competitive TCE landscape due to potential tolerability issues. With a projected peak revenue opportunity of only $1.8 billion by 2035, the company's other assets, including JANX013 and JANX014, may offer potential value drivers. However, failure to meet efficacy or safety expectations and competition from current and future therapies pose risks to the company's potential for success.

Janux Therapeutics (JANX) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 17% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Janux Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Janux Therapeutics (JANX) Forecast

Analysts have given Janux Therapeutics (JANX) a Buy based on their latest research and market trends.

According to 12 analysts, Janux Therapeutics (JANX) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Janux Therapeutics (JANX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.